Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarizotan for Dyskinesia in Parkinson's Disease
NCT00105508Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Sep 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyskinesia comparing Sarizotan with Placebo (2 arms). Primary endpoints: Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at 12 weeks and Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Items 18 to 31 at 12 weeks. Started Sep 2004; status: completed.
02
Drugs
sarizotan
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT00105508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105508.